• Police seek suspects in deadly birthday party shooting
  • Lawmakers launch inquires into U.S. boat strike
  • Nov. 29, 2025, 10:07 PM EST / Updated Nov. 30, 2025,…
  • Mark Kelly says troops ‘can tell’ what orders…

Be that!

contact@bethat.ne.com

 

Be That ! Menu   ≡ ╳
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics Politics
☰

Be that!

Savewith a NBCUniversal ProfileCreate your free profile or log in to save this articleOct. 31, 2025, 8:29 AM EDT / Updated Oct. 31, 2025, 10:04 AM EDTBy Michael Kosnar, Tom Winter, Jonathan Dienst, Kelly O’Donnell and Patrick SmithThe FBI arrested multiple suspects who were allegedly plotting a foiled “potential terrorist attack” in Michigan over the Halloween weekend, Director Kash Patel said Friday.“This morning the FBI thwarted a potential terrorist attack and arrested multiple subjects in Michigan who were allegedly plotting a violent attack over Halloween weekend,” Patel wrote in a statement on X.Four senior law enforcement officials familiar with the case said the FBI in Detroit apprehended a group of young individuals into custody today who were plotting some form of attack with a possible reference to Halloween.Those officials say the group has a nexus to some form of foreign extremism, but did not say if it was ISIS, Al Qaeda, or some other similar ideology. Officials stressed there is no current threat to the public,One official says some of the arrests occurred in Dearborn and Inkster, Michigan. Law enforcement was able to monitor the group in the greater Detroit area in the past several days at a minimum to make sure no actual attack happened, the officials said.A federal law enforcement source told NBC News that the FBI arrests took place in Dearborn and Inkster, cities outside of Detroit.Dearborn police confirmed in a Facebook post that the FBI carried out an operation there on Friday morning.“The Dearborn Police Department has been made aware that the FBI conducted operations in the City of Dearborn earlier this morning,” police said, before adding that there was no threat to the public.The case involves federal charges and arrests, but the court documents are sealed as of Friday morning.Michael KosnarMichael Kosnar is the Justice Department Producer for NBC News. Tom WinterTom Winter is NBC’s National Law Enforcement and Intelligence Correspondent. Jonathan DienstJonathan Dienst is chief justice contributor for NBC News and chief investigative reporter for WNBC-TV in New York.Kelly O’DonnellChief Justice and National Affairs CorrespondentPatrick SmithPatrick Smith is a London-based editor and reporter for NBC News Digital.Rebecca Shabad contributed.

admin - Latest News - October 31, 2025
admin
15 views 40 secs 0 Comments




The FBI arrested multiple suspects who were allegedly plotting a foiled “potential terrorist attack” in Michigan over the Halloween weekend, Director Kash Patel said Friday.“This morning the FBI thwarted a potential terrorist attack and arrested multiple subjects in Michigan who were allegedly plotting a violent attack over Halloween weekend,” Patel wrote in a statement on X.Four senior law enforcement officials familiar with the case said the FBI in Detroit apprehended a group of young



Source link

TAGS:
PREVIOUS
Oct. 31, 2025, 5:00 AM EDT / Updated Oct. 31, 2025, 8:16 AM EDTBy Peter Nicholas and Megan LebowitzWASHINGTON — Over the years, a genteel nonprofit organization called the Trust for the National Mall has raised money to help care for the cherry trees dotting the Tidal Basin. It upgraded the U.S. Park Police stables on the National Mall and hosted pickleball games on the grassy expanse between American monuments.Now it has a new assignment: handling the millions of dollars pouring in for President Donald Trump’s gilded White House ballroom. The nonpartisan group is serving as the steward for what Trump has said is more than $350 million in private donations from individuals, foundations and corporations to remake part of the old East Wing into a 90,000-square-foot ballroom. Donors have been instructed to direct their ballroom contributions to the trust, a tax-exempt nonprofit organization. Individual and corporate donors can typically deduct the amount they contributed from their federal income taxes. A person raising money for the ballroom told NBC News that they have been asking for donations of $2.5 million to $5 million and that the deduction is one reason people choose to give. The fundraiser, like others in this article, was granted anonymity to speak candidly. The White House said donors will be able to remain anonymous if they wish.The trust’s involvement in Trump’s project has plunged it into politically divisive terrain that it has avoided since its founding in 2007. Senators are demanding answers about what the trust knows about the ballroom and its donors and when it found out.“This nonpartisan, independent organization is about to be enmeshed in the very perilous quicksand of Donald Trump’s donation scheme for his ballroom,” Sen. Richard Blumenthal, D-Conn., said in an interview.Devoted to “restoring, preserving and enriching the National Mall,” the trust is now part of a project that is transforming the symbol of American history and power. Construction crews flattened the East Wing of the White House this month to make way for a ballroom that can seat nearly 1,000 people; in July, Trump said the addition wouldn’t touch the White House.In interviews, trust officials stressed that they’re playing only the limited role of managing the donations and have no say over the design or construction of the ballroom itself. The group is an official partner of the National Park Service, the federal agency that maintains the White House grounds. Traditionally, the trust assists the Park Service by raising private money for projects, thus defraying the cost to taxpayers.Over the summer, the Park Service approached the trust and asked whether it would handle the private donations for the ballroom, a trust staff member said.The group’s 14-member board discussed the request and agreed to take part, board member Eric Hoplin, who is CEO of the National Association of Wholesaler-Distributors, said in an interview. Neither he nor the staff member would say whether the group could have declined to participate.Asked whether the trust knew in advance that the East Wing would be torn down, Hoplin said, “Because we weren’t involved in the design or construction, we were learning about the evolution of the project as others have.”He made no apologies for the ballroom, pointing to past White House renovations that also drew public ire back in the day. “If you look to history and you think about Andrew Jackson’s addition of the North Portico and you look at Teddy Roosevelt’s addition of the West Wing, when you look at the Truman restoration, including the Truman Balcony, each of those projects in their time was controversial,” Hoplin said. “Now they’re widely accepted and in fact celebrated parts of the White House. So it’s not for us to judge the project. We’re the partner of the National Park Service, and we are playing this limited role.”Born out of a philanthropic impulse, the trust seems a throwback to an era that predated Trump’s rise. The ballroom project is an arranged marriage of sorts between MAGA and civic magnanimity.Chip Akridge, head of a local commercial real estate firm, would regularly jog through Washington to look at his properties. A friend urged him to inspect the Mall’s condition, and when he did, he saw it was “a disgrace,” he told a House committee in 2008. Akridge said he helped create the trust to restore the Mall’s luster.The East Wing was demolished to make room for Trump’s new ballroom.Andrew Harnik / Getty ImagesOver the years, the trust has led a string of efforts to improve the Mall and surrounding spaces. During Trump’s first term, it managed $4 million in private donations for a pair of White House projects: a tennis pavilion and a renovation of the Rose Garden. Trump paved over the garden grass after he returned to office.The group brought in volunteers to help with White House garden tours, along with experts to “shape” White House educational tours in President Joe Biden’s administration, the staff member said.Donors have been invited to “adopt” a cherry tree as part of the trust’s effort to preserve the 3,700-some cherry trees on the Tidal Basin. A total of $42,000 was raised in 2023 to help protect 40 trees. The group also worked to upgrade horse stables on the Mall that were first built in the 1970s, among other projects. And it marshals volunteers for smaller tasks, such as painting benches and laying mulch.Current board members aren’t Trump’s traditional MAGA allies. Some are past or present executives at corporations like Humana and Wells Fargo, while others are philanthropists who have supported cultural and artistic endeavors. The group’s president and CEO is Catherine Townsend, who was appointed in 2016. That year, she donated $250 to the Democratic presidential campaign of Hillary Clinton, campaign finance records show. Townsend also made a pair of $250 donations to the Democratic Congressional Campaign Committee in 2010. The trust didn’t make Townsend available for an interview and didn’t respond to questions about the donations.Since he took office, Trump has pushed hard to do away with diversity, equity and inclusion initiatives. The trust hosted “conversations” during Joe Biden’s presidency that amplified minority voices. One such event in 2021 focused on African Americans and the influential role they’ve played on the National Mall. Another one that year, “Herstory on America’s Civic Stage,” dealt with “important moments for America’s women.” A third celebrated Asian American and Pacific Island Heritage Month. This week, the White House fired all six members of the Commission of Fine Arts, an independent government agency that is expected to review Trump’s construction projects, including the ballroom. A White House official said it plans to replace them with people who are “more aligned with President Trump’s America First Policies.”Blumenthal and four other Democratic senators sent a letter to the trust and its governmental partner, the National Park Service, on Oct. 23 with a list of questions and a Nov. 7 deadline for answers. “Is the demolition consistent with the Trust’s mission to ‘preserve the National Mall as a symbol of our nation’s ideals and civic purpose?’” the senators asked.“What procedures are in place to pay for the project if costs exceed the amount raised via the Trust? Will taxpayers be liable for any potential costs of this project?” wrote Blumenthal and Sens. Elizabeth Warren and Edward Markey of Massachusetts, Ron Wyden of Oregon and Chris Van Hollen of Maryland.In a statement to NBC News, Warren said that “billionaires and giant corporations with business in front of the Trump administration are not coughing up millions of dollars to build Trump’s ballroom out of concern for the National Mall.”“The Trust for the National Mall appears to have become a vehicle for favor-seeking and possible corruption,” she said. “I’m pushing to find out if the Trust is facilitating wink-and-nod arrangements — and what these ballroom donors are getting in return.”The trust has not yet responded to the senators’ letter. In the past, the trust has raised comparatively modest amounts of money. In 2022, it received only about $2.2 million in contributions and grants, according to its IRS tax returns. Last year, it raised about $9.5 million.The ballroom project has attracted donations from major companies such as Google, Amazon, Apple, Microsoft and beyond. Comcast Corp., the parent company of NBCUniversal, was also on the White House list of donors. The trust staff member said that “financials can vary widely year over year based on projects being built or completed and where we are in a fundraising cycle.”The group has stepped up its fundraising efforts ahead of July 4, 2026, when the nation will celebrate its 250th anniversary. It has set out to raise $250 million, with the money going toward projects that include restoring the fountains of Lafayette Square, across the street from the White House.A former IRS official who reviewed the trust’s most recent tax return expressed doubts that the group is equipped to manage the ballroom donations.“The main thing is that this is not an organization that shows any indication of being able to have an inflow of hundreds of millions of dollars,” the person said, speaking on condition of anonymity.Hoplin voiced confidence the trust can do the job.“We have the capacity and the ability and the track record for a project of this magnitude,” he said.Peter NicholasPeter Nicholas is a senior White House reporter for NBC News.Megan LebowitzMegan Lebowitz is a politics reporter for NBC News.Christina Wilkie contributed.
NEXT
Sean ‘Diddy’ Combs transferred to N.J. federal prison
Related Post
November 1, 2025
Towns push back against police cameras that read billions of license plates per month
September 27, 2025
Sept. 27, 2025, 5:30 AM EDTBy Berkeley Lovelace Jr.For people who rely on certain prescription drugs, including weight loss, asthma and cancer medications, President Donald Trump’s post announcing 100% tariffs on foreign brand-name drugs offers little clarity on when — or if — medications might see price hikes. “Starting October 1st, 2025, we will be imposing a 100% Tariff on any branded or patented Pharmaceutical Product, unless a Company IS BUILDING their Pharmaceutical Manufacturing Plant in America,” Trump said on Truth Social late Thursday. “‘IS BUILDING’ will be defined as, ‘breaking ground’ and/or ‘under construction.’ There will, therefore, be no Tariff on these Pharmaceutical Products if construction has started.”Experts say Trump’s post raises a lot of questions. Here are five major ones. What drugs will be impacted?Trump’s post doesn’t specify whether brand-name drugmakers with an existing U.S. plant would be exempt, whether that exemption would include all their products, or whether it would only be for the drugs manufactured at the U.S. site. Novo Nordisk and Eli Lilly, makers of the weight loss drugs Wegovy and Zepound, respectively, have announced plans to invest in U.S. manufacturing. But it’s unclear if their intent to invest will warrant an exemption. On Tuesday, Lilly announced plans for a $6.5 billion manufacturing facility in Houston that will produce Zepbound and its other GLP-1 drug, Mounjaro, following a recent commitment to build a $5 billion plant near Richmond, Virginia. Novo Nordisk, a Danish company, said in June it would spend $4.1 billion to construct a second GLP-1 fill-finish plant in Clayton, North Carolina.AstraZeneca, which makes the asthma drug Symbicort, also announced in July that it will invest $50 billion over the next five years to expand its research and development and manufacturing footprint in the U.S. Many other popular brand-name drugs, however, are primarily manufactured overseas, particularly in Europe, said Rena Conti, an associate professor at Boston University’s Questrom School of Business.Botox, made by Allergen, and the cancer drug Keytruda from drugmaker Merck are made in Ireland. (Keytruda’s manufacturing has increasingly moved to the United States in recent years, but it’s not clear if that would earn an exemption from Trump’s tariffs.)Others, including some for blood and lung cancers, as well as vaccines, are made in places like India and China, Conti said. “I think what’s most at risk here are branded products that come from China and India,” she said. The E.U. and Japan already have trade agreements in place that cover pharmaceuticals, she added, and it’s unclear whether the new tariff will supersede that. Will patients see prices increase?Only 1 in 10 of the prescriptions filled in the U.S. are for brand-name drugs; the vast majority are for generics, which are much cheaper and will not be affected by these tariffs. Whether patients see price increases will depend on how many drugmakers receive exemptions — and on whether companies choose to pass those costs on to patients at the pharmacy counter, said Dr. Aaron Kesselheim, a professor of medicine at Harvard Medical School. ​​“Ultimately, tariffs are taxes on patients,” Kesselheim said, “and to the extent that drug companies see increases in cost due to tariffs, they will pass those costs on to patients.”Some companies may decide not to pass the costs along. So far, the 15% tariffs on imports from the E.U. haven’t translated into big price hikes for U.S. patients, Conti noted. To be sure, a 100% tariff would be far more costly for a company. Price hikes may not start right away, as drugmakers find out whether they qualify for an exemption. There also might be a lag since U.S. law prevents drugmakers from increasing the price of drugs faster than inflation.“What if you’re doing updates to the plant you currently have? What if you’re planning a facility? Do those count?” Kesselheim said. “It’s all very ambiguous.”Some patients may not notice additional price hikes at all, given how costly brand-name drugs already are in the U.S., said Arthur Caplan, the head of the Division of Medical Ethics at NYU Langone Medical Center in New York City. “I can certainly predict that some patients will immediately feel price increases that will shock them on some of these drugs,” Caplan said.Could insurers absorb the costs?Insurers and middlemen, known as pharmacy benefit managers, could try to negotiate drugmakers or absorb some of the tariff-related costs, Caplan said.It’s more likely, however, that they’d pass it on to patients in the short term, potentially in the form of a larger copay, he said.It’s not only patients with private insurance that should be worried about price hikes, Kesselheim said. Those who get their drugs covered through government health programs could also see price increases.“The government is the largest purchaser of prescription drugs in the market, through Medicare, Medicaid and the VA, so it’s really the government or government payers that are going to see the largest impact on price increases,” he said. Will tariffs spur more U.S. drug manufacturing?It’s unlikely, Kesselheim said. The decision to build a plant “is a complicated and expensive one” that requires several regulatory hurdles and years of planning.Conti noted that by the time new manufacturing plants are completed, Trump would likely be out of office.“It is somewhere between two years and five years to get new production facilities built,” she said, “and it can be in the millions of dollars depending on whether the product that you’re making is a small molecule drug or a biologic.”Even putting money back into an existing plant isn’t quick.“If you want to switch a line or retool a factory to make a product, then we’re talking about somewhere between 18 to 36 months to do that,” Conti said, “because you have to show the U.S. regulator that you can make it at this factory at scale, and the product is what it says it is, or is high quality and meets the quality standards of the U.S.”In a statement, Alex Schriver, a spokesperson for the trade group the Pharmaceutical Research and Manufacturers of America, said “most innovative medicines prescribed in America are already made in America” and companies continue to invest in the U.S.“Tariffs risk those plans because every dollar spent on tariffs is a dollar that cannot be invested in American manufacturing or the development of future treatments and cures,” Schriver said. “Medicines have historically been exempt from tariffs because they raise costs and could lead to shortages.”What about shortages?If Trump keeps his focus solely on brand-name drugs, U.S. patients are unlikely to face shortages, Kesselheim said.“Their profits are just so, so far beyond this tariff cost that they could probably be OK or raise the prices of the drugs,” he said. “They would probably not stop production as a result.”But that excludes, he added, some smaller companies who may make niche brand-name products and may not have the resources to take on the extra costs. If tariffs extend to generics, the risk is far greater, Caplan added. Unlike brand-name drugs, generic drugs are typically sold at close to the cost they’re made, he said, which makes it difficult for companies to justify the cost of building a new facility. They’d likely be forced to walk away from production or close their plants altogether.Berkeley Lovelace Jr.Berkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
October 24, 2025
Target cuts 1,800 jobs in first major layoff in years
October 11, 2025
Palestinians Begin Return Home As Ceasefire Takes Effect
Comments are closed.
Scroll To Top
  • Home
  • Travel
  • Culture
  • Lifestyle
  • Sport
  • Contact Us
  • Politics
© Copyright 2025 - Be That ! . All Rights Reserved